drugset / Trial / NCT02041546

Lung Lavage With Dilute Poractant Alfa for Meconium Aspiration Syndrome

NCT02041546

RandomizedParallel-groupOpen-labelTreatment

Summary

Meconium aspiration syndrome (MAS) is an important cause of severe respiratory failure in newborn infants. Treatment for MAS is mainly supportive but surfactant therapy might change the course of the disease. Aim of the study to evaluate whether lung lavage with dilute or bolus poractant alfa changes the duration of mechanical respiratory support or other outcomes in MAS.

Timeline

Start
2013-09
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Poractant alfa Other / unclassified 30 unknown Other
Comparator Poractant alfa Other / unclassified 100 mg/kg Other